GSK3B and cholangiocarcinoma: The association of a decrease in phosphorylation of GSK-3β (activation of its enzymatic activity), decrease in β-catenin and inhibition of CCA again suggests that the activation of GSK-3β may attenuate the growth of CCA by decreasing the expression of β-catenin.